Multiple Gene Expression Analysis Reveals Distinct Differences Between G2 and G3 Stage Breast Cancers, and Correlations of PKC Eta with MDR1, MRP and LRP Gene Expression

Overview

Journal Br J Cancer

Specialty Oncology

Date 1998 Feb 12

PMID 9459150

Citations 12

Authors

J Beck

B Bohnet

D Brugger

P Bader

J Dietl

R J Scheper

R Kandolf

C Liu

D Niethammer

V Gekeler

Affiliations

Soon will be listed here.

Abstract

A possible link between protein kinase C (PKC) and P-glycoprotein (P-gp)-mediated-multidrug resistance (MDR) was assumed from studies on MDR cell lines selected in vitro. The functional relevance of PKC for the MDR phenotype remains unclear, and the involvement of a particular PKC isozyme in clinically occurring drug resistance is not known. Recently, we have demonstrated significant correlations between the expression levels of the PKC eta isozyme and the MDR1 or MRP (multidrug resistance-associated protein) genes in blasts from patients with acute myelogenous leukaemia (AML) and in ascites cell aspirates from ovarian cancer patients. To extend these findings to further types of human tumours we analysed specimens from 64 patients with primary breast cancer for their individual expression levels of several MDR-associated genes (MDR1, MRP, LRP (lung cancer resistance-related protein), topoisomerase (Topo) II alpha/IIbeta, cyclin A and the PKC isozyme genes (alpha, beta1, beta2, eta, theta, and mu) by a cDNA-PCR approach. We found significantly enhanced mean values for MRP, LRP and PKC eta gene expression, but significantly decreased Topo II alpha and cyclin A gene expression levels in G2 tumours compared with G3. Remarkably, significant positive correlations between the MDR1, MRP or LRP gene expression levels and PKC eta were determined: MDR1/PKC eta (rs = +0.6451, P < 0.0001) n = 62; MRP/PKC eta (rs = +0.5454, P < 0.0001) n = 63; LRP/PKC eta (rs = +0.5436, P < 0.0001) n = 62; MRP/LRP (rs = +0.7703, P < 0.0001) and n = 62, MDR1/MRP (rs = +0.5042, P < 0.0001) n = 62. Our findings point to the occurrence of a multifactorial MDR in the clinics and to PKC eta as a possible key regulatory factor for up-regulation of a series of MDR-associated genes in different types of tumours.

Citing Articles

Emerging Significance of Ginsenosides as Potentially Reversal Agents of Chemoresistance in Cancer Therapy.

Xu J, Wan Y, Tang F, Chen L, Yang Y, Xia J Front Pharmacol. 2022; 12:720474.

PMID: 34975466 PMC: 8719627. DOI: 10.3389/fphar.2021.720474.

The Enigmatic Protein Kinase C-eta.

Basu A Cancers (Basel). 2019; 11(2).

PMID: 30781807 PMC: 6406448. DOI: 10.3390/cancers11020214.

PKCη promotes senescence induced by oxidative stress and chemotherapy.

Zurgil U, Ben-Ari A, Atias K, Isakov N, Apte R, Livneh E Cell Death Dis. 2014; 5:e1531.

PMID: 25412309 PMC: 4260739. DOI: 10.1038/cddis.2014.481.

Multidrug resistance in breast cancer: from in vitro models to clinical studies.

Wind N, Holen I Int J Breast Cancer. 2012; 2011:967419.

PMID: 22332018 PMC: 3276077. DOI: 10.4061/2011/967419.

The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity.

Ersvaer E, Olsnes Kittang A, Hampson P, Sand K, Gjertsen B, Lord J Toxins (Basel). 2011; 2(1):174-94.

PMID: 22069553 PMC: 3206618. DOI: 10.3390/toxins2010174.

References

Chirgwin J, Przybyla A, MacDonald R, Rutter W . Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979; 18(24):5294-9. DOI: 10.1021/bi00591a005. View

BLOOM H, Richardson W . Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11(3):359-77. PMC: 2073885. DOI: 10.1038/bjc.1957.43. View

Batist G, Tulpule A, Sinha B, KATKI A, Myers C, Cowan K . Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986; 261(33):15544-9. View

Gekeler V, FRESE G, Diddens H, Probst H . Expression of a P-glycoprotein gene is inducible in a multidrug-resistant human leukemia cell line. Biochem Biophys Res Commun. 1988; 155(2):754-60. DOI: 10.1016/s0006-291x(88)80559-x. View

Goldstein L, Galski H, Fojo A, Willingham M, Lai S, Gazdar A . Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989; 81(2):116-24. DOI: 10.1093/jnci/81.2.116. View

Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M . P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer. 1989; 60(6):815-8. PMC: 2247284. DOI: 10.1038/bjc.1989.372. View

Chambers T, McAvoy E, Jacobs J, Eilon G . Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem. 1990; 265(13):7679-86. View

Ro J, Sahin A, Ro J, Fritsche H, Hortobagyi G, Blick M . Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol. 1990; 21(8):787-91. DOI: 10.1016/0046-8177(90)90046-8. View

Pines J, Hunter T . Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature. 1990; 346(6286):760-3. DOI: 10.1038/346760a0. View

10.

Sato W, Yusa K, Naito M, Tsuruo T . Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Commun. 1990; 173(3):1252-7. DOI: 10.1016/s0006-291x(05)80921-0. View

11.

Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R . Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer. 1991; 27(2):155-8. DOI: 10.1016/0277-5379(91)90476-t. View

12.

Yu G, Ahmad S, Aquino A, Fairchild C, Trepel J, Ohno S . Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun. 1991; 3(6):181-9. DOI: 10.3727/095535491820873263. View

13.

Greif H, Ben-Chaim J, Shimon T, Bechor E, Eldar H, Livneh E . The protein kinase C-related PKC-L(eta) gene product is localized in the cell nucleus. Mol Cell Biol. 1992; 12(3):1304-11. PMC: 369563. DOI: 10.1128/mcb.12.3.1304-1311.1992. View

14.

Chaudhary P, Roninson I . Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993; 85(8):632-9. DOI: 10.1093/jnci/85.8.632. View

15.

Gekeler V, Boer R, Ise W, Sanders K, Schachtele C, Beck J . The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun. 1995; 206(1):119-26. DOI: 10.1006/bbrc.1995.1017. View

16.

Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V . Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol. 1995; 89(2):356-63. DOI: 10.1111/j.1365-2141.1995.tb03312.x. View

17.

Blobe G, Obeid L, Hannun Y . Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 1994; 13(3-4):411-31. DOI: 10.1007/BF00666107. View

18.

Germann U, Chambers T, Ambudkar S, Licht T, Cardarelli C, Pastan I . Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem. 1996; 271(3):1708-16. DOI: 10.1074/jbc.271.3.1708. View

19.

Clifford S, Neal D, Lunec J . Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. Br J Cancer. 1996; 73(5):659-66. PMC: 2074328. DOI: 10.1038/bjc.1996.115. View

20.

Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G . Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia. 1996; 10(3):426-33. View